Regulatory tracker
UK peptide regulation: monthly overview
Written and reviewed by the PeptideClear editorial team. · Best Business Loans Ltd (16833937)
Last updated:
26 items in the 35 days to 2026-11-12, 26 new since the previous run. This combines the MHRA's own published feed with one monthly web-search pass for ASA rulings, Trading Standards action and named-retailer enforcement, the things no regulator RSS feed reliably carries. It is a reporting record, not advice.
26
Items in this run
26
New since previous run
4
Distinct sources
This month, by source
Every item below restates a published source with a direct link. Nothing is paraphrased from secondary reporting.
| Date | Source | Item |
|---|---|---|
| 2026-11-11 | MHRA announcement | MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC). |
| 2026-11-09 | MHRA announcement | Investigational treatments for lung cancer, Huntington’s disease and Alzheimer's gain Innovation Passports through the Innovative Licensing and Access Pathway Three innovative medicines with the potential to meet unmet needs in lung cancer, Huntington’s disease and Alzheimer’s disease have been given Innovation Passports, the Medicines and Healthcare products Regulatory Agency… |
| 2026-11-05 | MHRA Drug Safety Update | Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Following a review of these cases and associated evidence, the… |
| 2026-11-05 | MHRA announcement | MHRA sets out approach to strengthen patient and public involvement and engagement in medicines and medical device regulation New plan will broaden participation and make clearer how patient experience informs regulatory decisions, safety and innovation |
| 2026-11-04 | ASA | ASA bans four ads promoting prescription-only weight-loss pills (Voy, Juniper, MedExpress) The ASA announced it had banned four ads for prescription-only oral weight-loss pills, covering a Voy bus ad and video-on-demand ad, a Juniper YouTube ad and a MedExpress Instagram ad, because they promoted a prescription-only medicine to the public. The date is that of the trade press report, and the article gives no formal ruling date and links no ASA ruling pages. |
| 2026-11-04 | MHRA announcement | MHRA guidance on its assessment of non-clinical data generated outside OECD system MHRA issues new guidance on its approach to clinical trial applications that rely on non-clinical safety data generated outside the OECD Mutual Acceptance of Data system. |
| 2026-11-03 | MHRA announcement | Clinical trials for medicines: Inclusion and Diversity Plan pilot findings published The Health Research Authority (HRA) has published the findings from its pilot on researchers and sponsors of clinical trials and clinical investigations developing and submitting an Inclusion and Diversity Plan. |
| 2026-11-02 | MHRA announcement | MHRA launches patient safety essay competition for MedSafetyWeek The MHRA reminds patients, parents, carers and healthcare professionals to report suspected side effects through the Yellow Card scheme for MedSafetyWeek 2026. |
| 2026-10-30 | MHRA announcement | MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders Children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, can now be treated with Casgevy (exagamglogene autotemcel), following an extension of its UK authorisation by the MHRA. |
| 2026-10-30 | MHRA announcement | Triheptanoin (Dojolvi) approved to treat adults and children with a group of rare inherited disorders MHRA approves triheptanoin to treat adult and paediatric patients with a group of rare inherited disorders. |
| 2026-10-27 | MHRA announcement | New MHRA research puts needle-free Strep A vaccine within reach Pioneering study by MHRA scientists advances innovative approach to vaccination and promise of vaccine against Strep A. |
| 2026-10-26 | MHRA Drug Safety Update | #MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app The annual #MedSafetyWeek campaign is taking place from 2 to 8 November 2026 to promote the importance of reporting side effects from medicines and medical device incidents. This year's theme is ‘Side effects:… |
| 2026-10-23 | MHRA announcement | MHRA approves new oral treatment for moderate to severe plaque psoriasis MHRA approves new oral treatment for moderate to severe plaque psoriasis |
| 2026-10-23 | MHRA announcement | MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review. |
| 2026-10-21 | MHRA announcement | Government confirms indefinite recognition of CE marked medical devices Patients across Great Britain will have continued access to medical devices and in vitro diagnostic devices (IVDs) already approved for the EU market. |
| 2026-10-20 | MHRA Drug Safety Update | IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review Following advice from the Commission on Human Medicines (CHM), the MHRA has concluded that the benefit-risk balance for the IXCHIQ chikungunya vaccine is no longer considered favourable and the UK marketing authorisation… |
| 2026-10-19 | MHRA announcement | MHRA consults on proposals to allow schools to keep spare adrenaline nasal sprays on site The MHRA is now consulting on proposals that would give schools an additional option to support children at risk of life-threatening allergic reactions. |
| 2026-10-19 | MHRA announcement | UK regulator brings new AI and MedTech agenda to AdvaMed UK’s Medicines and Healthcare products Regulatory Agency (MHRA) sets out its next phase of MedTech and AI regulation to US industry leaders at AdvaMed 2026. |
| 2026-10-19 | MHRA announcement | MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 19 October 2026, authorised plozasiran (Redemplo) |
| 2026-10-15 | MHRA Drug Safety Update | Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction New safety measures are now being implemented to improve how the risks of suicidal thoughts and behaviours and persistent sexual dysfunction are communicated to patients taking antidepressant medications. |
| 2026-10-15 | MHRA announcement | MHRA introduces new safeguards to strengthen antidepressant safety information following major review New and updated patient information for antidepressant medicines to be introduced following an extensive review involving patients, families and independent experts. |
| 2026-10-15 | MHRA announcement | Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police Fake weight loss medicines worth approximately £2 million were seized last night in a raid executed by the Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Police. |
| 2026-10-14 | MHRA | Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police The MHRA and West Midlands Police raided an industrial unit in Birmingham on 14 October and seized over 12,000 fake retatrutide and tirzepatide pens plus packaging for around 30,000 more products; no retailer was named in the search excerpts and I did not open the full page. |
| 2026-10-14 | MHRA announcement | MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients across all four nations… |
| 2026-10-13 | MHRA announcement | MHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes The new treatment option is administered once weekly, potentially reducing the number of injections from up to 365 a year to 52 for some adults with type 2 diabetes. |
| 2026-10-09 | MHRA announcement | MHRA Chair Professor Anthony Harnden: Bringing our strategy to life – listening, learning, and looking ahead In the final instalment of our strategy blog series, MHRA Chair Professor Anthony Harnden reflects on the insights shared throughout the series and how innovation and collaboration across the UK are shaping the future of… |
| Date | Source | Item | Summary |
|---|---|---|---|
| 2026-11-11 | MHRA announcement | MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer | The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC). |
| 2026-11-09 | MHRA announcement | Investigational treatments for lung cancer, Huntington’s disease and Alzheimer's gain Innovation Passports through the Innovative Licensing and Access Pathway | Three innovative medicines with the potential to meet unmet needs in lung cancer, Huntington’s disease and Alzheimer’s disease have been given Innovation Passports, the Medicines and Healthcare products Regulatory Agency… |
| 2026-11-05 | MHRA Drug Safety Update | Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat | There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Following a review of these cases and associated evidence, the… |
| 2026-11-05 | MHRA announcement | MHRA sets out approach to strengthen patient and public involvement and engagement in medicines and medical device regulation | New plan will broaden participation and make clearer how patient experience informs regulatory decisions, safety and innovation |
| 2026-11-04 | ASA | ASA bans four ads promoting prescription-only weight-loss pills (Voy, Juniper, MedExpress) | The ASA announced it had banned four ads for prescription-only oral weight-loss pills, covering a Voy bus ad and video-on-demand ad, a Juniper YouTube ad and a MedExpress Instagram ad, because they promoted a prescription-only medicine to the public. The date is that of the trade press report, and the article gives no formal ruling date and links no ASA ruling pages. |
| 2026-11-04 | MHRA announcement | MHRA guidance on its assessment of non-clinical data generated outside OECD system | MHRA issues new guidance on its approach to clinical trial applications that rely on non-clinical safety data generated outside the OECD Mutual Acceptance of Data system. |
| 2026-11-03 | MHRA announcement | Clinical trials for medicines: Inclusion and Diversity Plan pilot findings published | The Health Research Authority (HRA) has published the findings from its pilot on researchers and sponsors of clinical trials and clinical investigations developing and submitting an Inclusion and Diversity Plan. |
| 2026-11-02 | MHRA announcement | MHRA launches patient safety essay competition for MedSafetyWeek | The MHRA reminds patients, parents, carers and healthcare professionals to report suspected side effects through the Yellow Card scheme for MedSafetyWeek 2026. |
| 2026-10-30 | MHRA announcement | MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders | Children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, can now be treated with Casgevy (exagamglogene autotemcel), following an extension of its UK authorisation by the MHRA. |
| 2026-10-30 | MHRA announcement | Triheptanoin (Dojolvi) approved to treat adults and children with a group of rare inherited disorders | MHRA approves triheptanoin to treat adult and paediatric patients with a group of rare inherited disorders. |
| 2026-10-27 | MHRA announcement | New MHRA research puts needle-free Strep A vaccine within reach | Pioneering study by MHRA scientists advances innovative approach to vaccination and promise of vaccine against Strep A. |
| 2026-10-26 | MHRA Drug Safety Update | #MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app | The annual #MedSafetyWeek campaign is taking place from 2 to 8 November 2026 to promote the importance of reporting side effects from medicines and medical device incidents. This year's theme is ‘Side effects:… |
| 2026-10-23 | MHRA announcement | MHRA approves new oral treatment for moderate to severe plaque psoriasis | MHRA approves new oral treatment for moderate to severe plaque psoriasis |
| 2026-10-23 | MHRA announcement | MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults | As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review. |
| 2026-10-21 | MHRA announcement | Government confirms indefinite recognition of CE marked medical devices | Patients across Great Britain will have continued access to medical devices and in vitro diagnostic devices (IVDs) already approved for the EU market. |
| 2026-10-20 | MHRA Drug Safety Update | IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review | Following advice from the Commission on Human Medicines (CHM), the MHRA has concluded that the benefit-risk balance for the IXCHIQ chikungunya vaccine is no longer considered favourable and the UK marketing authorisation… |
| 2026-10-19 | MHRA announcement | MHRA consults on proposals to allow schools to keep spare adrenaline nasal sprays on site | The MHRA is now consulting on proposals that would give schools an additional option to support children at risk of life-threatening allergic reactions. |
| 2026-10-19 | MHRA announcement | UK regulator brings new AI and MedTech agenda to AdvaMed | UK’s Medicines and Healthcare products Regulatory Agency (MHRA) sets out its next phase of MedTech and AI regulation to US industry leaders at AdvaMed 2026. |
| 2026-10-19 | MHRA announcement | MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome | The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 19 October 2026, authorised plozasiran (Redemplo) |
| 2026-10-15 | MHRA Drug Safety Update | Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction | New safety measures are now being implemented to improve how the risks of suicidal thoughts and behaviours and persistent sexual dysfunction are communicated to patients taking antidepressant medications. |
| 2026-10-15 | MHRA announcement | MHRA introduces new safeguards to strengthen antidepressant safety information following major review | New and updated patient information for antidepressant medicines to be introduced following an extensive review involving patients, families and independent experts. |
| 2026-10-15 | MHRA announcement | Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police | Fake weight loss medicines worth approximately £2 million were seized last night in a raid executed by the Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Police. |
| 2026-10-14 | MHRA | Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police | The MHRA and West Midlands Police raided an industrial unit in Birmingham on 14 October and seized over 12,000 fake retatrutide and tirzepatide pens plus packaging for around 30,000 more products; no retailer was named in the search excerpts and I did not open the full page. |
| 2026-10-14 | MHRA announcement | MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines | The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients across all four nations… |
| 2026-10-13 | MHRA announcement | MHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes | The new treatment option is administered once weekly, potentially reducing the number of injections from up to 365 a year to 52 for some adults with type 2 diabetes. |
| 2026-10-09 | MHRA announcement | MHRA Chair Professor Anthony Harnden: Bringing our strategy to life – listening, learning, and looking ahead | In the final instalment of our strategy blog series, MHRA Chair Professor Anthony Harnden reflects on the insights shared throughout the series and how innovation and collaboration across the UK are shaping the future of… |
Source: gov.uk MHRA feeds plus a monthly web-search pass for ASA, Trading Standards and enforcement news
View as plain-text Markdown
### UK peptide regulation items for 2026-11, by date and source | Date | Source | Item | Summary | | --- | --- | --- | --- | | 2026-11-11 | MHRA announcement | MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced anal cancer | The Medicines and Healthcare products Regulatory Agency (MHRA) has approved retifanlimab (ZYNYZ) for the treatment of adults with squamous cell carcinoma of the anal canal (SCAC). | | 2026-11-09 | MHRA announcement | Investigational treatments for lung cancer, Huntington’s disease and Alzheimer's gain Innovation Passports through the Innovative Licensing and Access Pathway | Three innovative medicines with the potential to meet unmet needs in lung cancer, Huntington’s disease and Alzheimer’s disease have been given Innovation Passports, the Medicines and Healthcare products Regulatory Agency… | | 2026-11-05 | MHRA Drug Safety Update | Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat | There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Following a review of these cases and associated evidence, the… | | 2026-11-05 | MHRA announcement | MHRA sets out approach to strengthen patient and public involvement and engagement in medicines and medical device regulation | New plan will broaden participation and make clearer how patient experience informs regulatory decisions, safety and innovation | | 2026-11-04 | ASA | ASA bans four ads promoting prescription-only weight-loss pills (Voy, Juniper, MedExpress) | The ASA announced it had banned four ads for prescription-only oral weight-loss pills, covering a Voy bus ad and video-on-demand ad, a Juniper YouTube ad and a MedExpress Instagram ad, because they promoted a prescription-only medicine to the public. The date is that of the trade press report, and the article gives no formal ruling date and links no ASA ruling pages. | | 2026-11-04 | MHRA announcement | MHRA guidance on its assessment of non-clinical data generated outside OECD system | MHRA issues new guidance on its approach to clinical trial applications that rely on non-clinical safety data generated outside the OECD Mutual Acceptance of Data system. | | 2026-11-03 | MHRA announcement | Clinical trials for medicines: Inclusion and Diversity Plan pilot findings published | The Health Research Authority (HRA) has published the findings from its pilot on researchers and sponsors of clinical trials and clinical investigations developing and submitting an Inclusion and Diversity Plan. | | 2026-11-02 | MHRA announcement | MHRA launches patient safety essay competition for MedSafetyWeek | The MHRA reminds patients, parents, carers and healthcare professionals to report suspected side effects through the Yellow Card scheme for MedSafetyWeek 2026. | | 2026-10-30 | MHRA announcement | MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders | Children aged five and over with severe sickle-cell disease and transfusion-dependent β-thalassemia, can now be treated with Casgevy (exagamglogene autotemcel), following an extension of its UK authorisation by the MHRA. | | 2026-10-30 | MHRA announcement | Triheptanoin (Dojolvi) approved to treat adults and children with a group of rare inherited disorders | MHRA approves triheptanoin to treat adult and paediatric patients with a group of rare inherited disorders. | | 2026-10-27 | MHRA announcement | New MHRA research puts needle-free Strep A vaccine within reach | Pioneering study by MHRA scientists advances innovative approach to vaccination and promise of vaccine against Strep A. | | 2026-10-26 | MHRA Drug Safety Update | #MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and app | The annual #MedSafetyWeek campaign is taking place from 2 to 8 November 2026 to promote the importance of reporting side effects from medicines and medical device incidents. This year's theme is ‘Side effects:… | | 2026-10-23 | MHRA announcement | MHRA approves new oral treatment for moderate to severe plaque psoriasis | MHRA approves new oral treatment for moderate to severe plaque psoriasis | | 2026-10-23 | MHRA announcement | MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults | As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review. | | 2026-10-21 | MHRA announcement | Government confirms indefinite recognition of CE marked medical devices | Patients across Great Britain will have continued access to medical devices and in vitro diagnostic devices (IVDs) already approved for the EU market. | | 2026-10-20 | MHRA Drug Safety Update | IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review | Following advice from the Commission on Human Medicines (CHM), the MHRA has concluded that the benefit-risk balance for the IXCHIQ chikungunya vaccine is no longer considered favourable and the UK marketing authorisation… | | 2026-10-19 | MHRA announcement | MHRA consults on proposals to allow schools to keep spare adrenaline nasal sprays on site | The MHRA is now consulting on proposals that would give schools an additional option to support children at risk of life-threatening allergic reactions. | | 2026-10-19 | MHRA announcement | UK regulator brings new AI and MedTech agenda to AdvaMed | UK’s Medicines and Healthcare products Regulatory Agency (MHRA) sets out its next phase of MedTech and AI regulation to US industry leaders at AdvaMed 2026. | | 2026-10-19 | MHRA announcement | MHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome | The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 19 October 2026, authorised plozasiran (Redemplo) | | 2026-10-15 | MHRA Drug Safety Update | Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunction | New safety measures are now being implemented to improve how the risks of suicidal thoughts and behaviours and persistent sexual dysfunction are communicated to patients taking antidepressant medications. | | 2026-10-15 | MHRA announcement | MHRA introduces new safeguards to strengthen antidepressant safety information following major review | New and updated patient information for antidepressant medicines to be introduced following an extensive review involving patients, families and independent experts. | | 2026-10-15 | MHRA announcement | Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police | Fake weight loss medicines worth approximately £2 million were seized last night in a raid executed by the Medicines and Healthcare products Regulatory Agency (MHRA) and West Midlands Police. | | 2026-10-14 | MHRA | Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police | The MHRA and West Midlands Police raided an industrial unit in Birmingham on 14 October and seized over 12,000 fake retatrutide and tirzepatide pens plus packaging for around 30,000 more products; no retailer was named in the search excerpts and I did not open the full page. | | 2026-10-14 | MHRA announcement | MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines | The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients across all four nations… | | 2026-10-13 | MHRA announcement | MHRA authorises Onswik (insulin efsitora alfa) for adults with type 2 diabetes | The new treatment option is administered once weekly, potentially reducing the number of injections from up to 365 a year to 52 for some adults with type 2 diabetes. | | 2026-10-09 | MHRA announcement | MHRA Chair Professor Anthony Harnden: Bringing our strategy to life – listening, learning, and looking ahead | In the final instalment of our strategy blog series, MHRA Chair Professor Anthony Harnden reflects on the insights shared throughout the series and how innovation and collaboration across the UK are shaping the future of… | Source: gov.uk MHRA feeds plus a monthly web-search pass for ASA, Trading Standards and enforcement news
“MHRA rows come straight from a government feed and are as reliable as that feed. ASA, Trading Standards and Companies House rows come from a monthly search pass, which finds what is publicly indexed at the time it runs, not a comprehensive legal record. Treat an absence of ASA rulings in a given month as no ruling was published where our search looked, not as proof nothing happened.”
Previous months
- 2026-10: 15 items
- 2026-08: 24 items
Methodology
- MHRA rows: the same gov.uk news and communications feed and Drug Safety Update feed used on the MHRA tracker, filtered to the last 35 days.
- ASA, Trading Standards and Companies House rows: one scoped web-search pass, run once a month, asked specifically for peptide-advertising rulings, enforcement action naming a UK peptide retailer, and relevant CAP Code guidance. Only items with a real, checkable source URL are included.
- Cadence: this page updates once a month, not continuously. Check the fetch date below for currency.
- This replaces manual, ad hoc checking of ASA and enforcement news with a scheduled pass, but it is still a search of what is publicly indexed, not a subscription to a regulator's own alert system.
Last fetched 2026-11-12. PeptideClear is editorial. We do not prescribe, dispense or sell medicines.
Check it yourself: the official sources
PeptideClear is editorial. Nothing here replaces the regulator, and you should not take our word for any of it. These are the official UK destinations where the underlying position is published, free to read and open to anyone.
MHRA
MHRA Products portalThe Summary of Product Characteristics and Patient Information Leaflet for every medicine licensed in the UK. This is the authoritative document for what a medicine is licensed to do.
MHRA
Drug Safety UpdateThe MHRA monthly bulletin of safety advice for prescribers and patients. Where new risks and product information changes are formally announced.
MHRA
Report a fake or illegally supplied medicineThe MHRA route for reporting a website or seller supplying medicines illegally, and for reporting a product you believe is counterfeit.
Advertising Standards Authority
CAP Code and ASA rulingsThe UK advertising rules, including the ban on advertising prescription-only medicines to the public, and the published rulings that show how they are applied.
World Anti-Doping Agency
WADA Prohibited ListThe annually updated list of substances and methods banned in sport. Many research peptides sit under S0 or S2. UK Anti-Doping enforces it on tested athletes.
legislation.gov.uk
Human Medicines Regulations 2012The legislation that defines what counts as a medicine in the UK, and what constitutes illegal supply. A product marketed with medicinal claims is regulated as a medicine regardless of how it is labelled.
Our live data trackers
PeptideClear maintains these as refreshable datasets rather than one-off articles. Each carries its own source, methodology and last-updated date.
Live data tracker
UK GLP-1 prescribing tracker →
Monthly NHS England primary-care prescribing volumes for GLP-1 medications, rebuilt as each new month publishes. Dated chart, month-by-month table, full methodology.
Source: NHSBSA English Prescribing Dataset
Live data tracker
UK peptide clinical-trials tracker →
Registered interventional trials for every research peptide we track, by phase and recruitment status, linking through to each compound record.
Source: ClinicalTrials.gov and ISRCTN
Live data tracker
MHRA enforcement and safety tracker →
Every MHRA safety alert, enforcement action and drug safety update relevant to weight-loss medicines and peptides, dated and linked to the gov.uk original.
Source: gov.uk / MHRA
Live data tracker
UK research-peptide price index →
Headline price per milligram across the UK research-peptide retailers we score, so a price can be read against the market rather than in isolation.
Source: PeptideClear retailer survey
Live data tracker
PeptideClear Trust Index →
156 UK sellers assessed for free across three baseline measures (Testing Transparency, Business Transparency, Responsible Practice), independently, on the Which? / Defaqto model. Testing Transparency alone draws on six observable certificate-of-analysis signals, reproducible from the published data.
Source: PeptideClear methodology
Live data tracker
Data API and MCP server →
Read-only, no-auth REST API and MCP server over the full scored dataset: corporate identity, regulatory status, CoA verification signals. CC BY 4.0.
Source: PeptideClear, live data